Suppr超能文献

射频消融治疗儿童复发性肝细胞癌:单中心经验。

Radiofrequency ablation for pediatric recurrent hepatocellular carcinoma: a single-center experience.

机构信息

Department of Medical Ultrasonics, Institute of Diagnostic and Interventional Ultrasound, The First Affiliated Hospital of Sun Yat-sen University, 58 Zhongshan Road 2, Guangzhou, 510080, China.

出版信息

BMC Med Imaging. 2023 Dec 6;23(1):202. doi: 10.1186/s12880-023-01159-3.

Abstract

PURPOSE

To summarize our single-center experience with percutaneous ultrasound (US)-guided radiofrequency ablation (RFA) for pediatric recurrent hepatocellular carcinoma (RHCC).

METHODS

From September 2007 to September 2021, patients under 18 who underwent percutaneous US-guided RFA for RHCC were retrospectively enrolled in this study. Local effectiveness, complications, local tumor progression (LTP), progression free survival (PFS), and overall survival (OS) were evaluated.

RESULTS

A total of 10 patients (9 male and 1 female; mean age, 11.7 ± 4 years ; age range, 6-17 years) with 15 intrahepatic RHCC lesions were enrolled in this study. Complete ablation (CA) was achieved in 14 out of 15 lesions (93.3%) after the first RFA. During the follow-up (mean, 63.1 ± 18 months; range, 5.3-123.3 months), LTP did not occur. Five patients died including three with tumor progression and one with liver failure. The accumulative one- and three-year PFS rates were 30% and 10%, respectively. The accumulative one- and three-year OS rates were 77.8% and 44.4%, respectively.

CONCLUSIONS

Our single-center experience suggests the safety and feasibility of percutaneous US-guided RFA for pediatric RHCC.

摘要

目的

总结我们单中心经皮超声(US)引导射频消融(RFA)治疗小儿复发性肝细胞癌(RHCC)的经验。

方法

本研究回顾性纳入 2007 年 9 月至 2021 年 9 月期间在我院接受经皮 US 引导 RFA 治疗 RHCC 的 18 岁以下患者。评估局部疗效、并发症、局部肿瘤进展(LTP)、无进展生存期(PFS)和总生存期(OS)。

结果

本研究共纳入 10 例(9 男 1 女;平均年龄 11.7±4 岁;年龄范围 6-17 岁)15 个肝内 RHCC 病灶。15 个病灶中 14 个(93.3%)在首次 RFA 后达到完全消融(CA)。在随访期间(平均 63.1±18 个月;范围 5.3-123.3 个月),未发生 LTP。5 例患者死亡,包括 3 例肿瘤进展和 1 例肝功能衰竭。累积 1 年和 3 年的 PFS 率分别为 30%和 10%。累积 1 年和 3 年的 OS 率分别为 77.8%和 44.4%。

结论

我们的单中心经验表明,经皮 US 引导 RFA 治疗小儿 RHCC 是安全可行的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c22b/10702076/8a9f5c9377df/12880_2023_1159_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验